C0073709||Ruscogenin
C0917798||Cerebral Ischemia
C0005854||Blood-Brain Barrier
C1448239||thiredoxin-interactive protein
C3272080||NLRP3 Inflammasome Activation
C1518102||MAPK Pathway
C0073709||Ruscogenin
C0038317||steroid
C0072845||sapogenin
C1046253||Ophiopogon japonicus
C1148560||molecular action
C0005854||blood-brain barrier
C0005854||blood-brain barrier
C0038454||stroke
C2603343||study
C0073709||ruscogenin
C0005854||blood-brain barrier
C0740391||middle cerebral artery occlusion
C3854511||reperfusion
C0740391||MCAO
C3854511||R
C0026809||mice
C4236781||oxygen-glucose deprivation
C4236781||OGD
C0026809||mouse
C0006104||brain
C0225336||endothelial cells
C0225336||bEnd.3
C1533734||administration
C0073709||ruscogenin
C0751955||brain infarction
C0013604||edema
C0184511||improved
C0521654||neurological deficits
C0428714||cerebral brain flow
C0428714||cerebral brain flow
C0184511||ameliorated
C0010957||damage
C0015205||evans blue
C0015205||evans blue
C4281748||leakage
C0041904||upregulated
C1171362||expression
C3494363||tight junctions
C3494363||tight junctions
C0740391||MCAO
C3854511||R
C0026809||mice
C0073709||ruscogenin
C0087111||treatment
C0007620||cell viability
C0147866||sodium fluorescein
C4281748||leakage
C0443264||modulated
C3494363||tight junctions
C1171362||expression
C4236781||OGD
C0225336||bEnd.3 cells
C0073709||ruscogenin
C1171362||expression
C0021753||interleukin-1β
C0021753||interleukin-1β
C0534519||caspase-1
C1171362||expression
C4255055||Nucleotide-binding domain (NOD)-like receptor family, pyrin domain containing 3
C1528260||NLRP3
C1448239||thiredoxin-interactive protein
C1448239||thiredoxin-interactive protein
C0073709||ruscogenin
C0162772||reactive oxygen species
C0162772||reactive oxygen species
C1518102||mitogen-activated protein kinase (MAPK) pathway
C4236781||OGD
C0225336||bEnd.3 cells
C0243095||findings
C0233820||insights
C0185125||application
C0199176||prevention
C0087111||treatment
C0948008||ischemic stroke